A Universal Transfection Reagent for High Efficiency mRNA Delivery

mRNA-In? Transfection Reagent was developed by members of the scientific team that invented Lipofectamine? and Lipofectamine? 2000 and specifically formulated for in vitro mRNA delivery. Maximum RNA delivery is achieved with mRNA-In? using lower amounts of mRNA than other reagents, reducing experimental costs and significantly lowering toxicity. Across a wide range of cell types, mRNA-In? has shown to produce exceptionally high transfection efficiency while maintaining optimal cell health and viability.

Features

• Requires low amounts of RNA - reduce cost and potential off-target toxicity effects with low amounts of RNA requirements.
  

•  Transfects a variety of cell lines with as little as 2 pg/cell of mRNA

• High expression, low toxicity - achieve high mRNA efficiency while maintaining optimal cell health for uncompromised experiment results.
  

• Robust, versatile performance - produce efficient transfection across a wide range of cell type, including stem cells and primary cells.

Applications

mRNA-In? Transfection Reagent is ideal for mRNA delivery for various applications, such as protein expression and iPSC-reprogramming. Data below also shows mRNA-In? significantly outperforms competitor reagents, typically achieving 90% or greater transfection efficiency across a wide range of cell types.

• Making the Optimal Messenger RNA for Gene Therapy Applications.pdf [ TriLink]

• A Reproducible, Efficient and User-friendly RNA Reprogramming System.pdf [ESIBio]

Delivers Maximum Transfection Efficiency using Low Amounts of mRNA

Data below show commonly used cell types transfected with mRNA-In? Transfection Reagent using various amounts of mRNA. Cells were plated in 24-well plates to give 60-70% confluence the day of transfection. GFP-mRNA containing 5-methlycytosine and psuedouridine were complexed with various amounts of mRNA-In? in a total of 50μl of OptiMEM?.  For each experiment mRNA /mRNA-In? complexes were added to cells, mixed, and incubated at 37oC in 5% CO2.  Cells were observed 24 hours following transfection. 

Higher  Expression, Significantly Outperforms the Leading Competitors

Below, SH-SY5Y (neuroblastoma cells), HDF (human dermal fibroblasts), HUVEC (human umbilical vein endothelial cells), HeLa and adipose-derived Mesenchymal Stem Cells (MSCs) were transfected with mRNA-In? or MessengerMAX? (Life Technologies) using low amounts of mRNA (100ng). Cells were plated in 24-well plates to give 60-70% confluence the day of transfection. GFP-mRNA containing 5-methlycytosine and psuedouridine were complexed with the various amounts of mRNA-In? (see chart legends). RNA/reagent complexes were added to the cells, mixed, and incubated at 37oC in 5% CO2 overnight.  Cells were analyzed by a fluorescence plate reader and microscopy 24 hours post-transfection. Error bars represent the standard deviation of triplicate wells. The data below shows mRNA-In? provides significantly higher transfection efficiency than the competitor reagent.